Calidi Biotherapeutics, Inc. Redeemable Warrants, each whole warrant exercisable for 1/10th of a share of Common Stock at an exercise price of $115.00
CLDI.WS
CLDI.WS was delisted on the 17th of October, 2024.
21 hedge funds and large institutions have $1.13M invested in Calidi Biotherapeutics, Inc. Redeemable Warrants, each whole warrant exercisable for 1/10th of a share of Common Stock at an exercise price of $115.00 in 2023 Q2 according to their latest regulatory filings, with 0 funds opening new positions, 1 increasing their positions, 5 reducing their positions, and 2 closing their positions.
1,081% more call options, than puts
Call options by funds: $921K | Put options by funds: $78K
81% more capital invested
Capital invested by funds: $623K → $1.13M (+$506K)
9% less funds holding
Funds holding: 23 → 21 (-2)
80% less repeat investments, than reductions
Existing positions increased: 1 | Existing positions reduced: 5
100% less first-time investments, than exits
New positions opened: 0 | Existing positions closed: 2
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
FTUS
Flow Traders U.S.
New York
|
+$9 |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
SCM
Shaolin Capital Management
Miami,
Florida
|
-$48.5K |
| 2 |
Parallax Volatility Advisers
San Francisco,
California
|
-$5.84K |
| 3 |
SAMU
SONA Asset Management (US)
New York
|
-$3.73K |
| 4 |
CAC
Cowen and Company
New York
|
-$2.26K |
| 5 |
AGM
Alpine Global Management
New York
|
-$32 |
CLDI.WS Hedge Fund Activity: Q2 2023 in Review
21 of the 6,383 institutional investors tracked by Wall St. Rank reported a position in Calidi Biotherapeutics, Inc. Redeemable Warrants, each whole warrant exercisable for 1/10th of a share of Common Stock at an exercise price of $115.00 (CLDI.WS) for Q2 2023, worth a combined $1.13M — up 81% from $623K a quarter earlier.
Sellers outnumbered buyers: 2 funds closed out of CLDI.WS and 0 opened new positions — a net loss of 2 holders — while 5 trimmed existing stakes and 1 added.
The largest buyer was Flow Traders U.S., adding an estimated $9. The largest seller was Shaolin Capital Management, exiting entirely with an estimated $48.5K sold.
- 21 institutional investors held Calidi Biotherapeutics, Inc. Redeemable Warrants, each whole warrant exercisable for 1/10th of a share of Common Stock at an exercise price of $115.00 (CLDI.WS) as of Q2 2023, down from 23 in Q1 2023.
- Funds reported $1.13M of Calidi Biotherapeutics, Inc. Redeemable Warrants, each whole warrant exercisable for 1/10th of a share of Common Stock at an exercise price of $115.00 stock for Q2 2023, up 81% quarter-over-quarter.
- 0 funds opened new Calidi Biotherapeutics, Inc. Redeemable Warrants, each whole warrant exercisable for 1/10th of a share of Common Stock at an exercise price of $115.00 positions in Q2 2023 and 2 closed out, a net change of -2 holders.
- The largest Calidi Biotherapeutics, Inc. Redeemable Warrants, each whole warrant exercisable for 1/10th of a share of Common Stock at an exercise price of $115.00 buyer in Q2 2023 was Flow Traders U.S., an estimated $9 added.
- The largest Calidi Biotherapeutics, Inc. Redeemable Warrants, each whole warrant exercisable for 1/10th of a share of Common Stock at an exercise price of $115.00 seller in Q2 2023 was Shaolin Capital Management, an estimated $48.5K sold.
Based on aggregated 13F filings for Q2 2023.